Clinical Immunology, Neuropharmacology and Drug Development

Hari Shanker Sharma is the Director of International Experimental Central Nervous System (CNS) Injury and Repair (IECNSIR) at University Hospital, Uppsala University, Sweden. He is a qualified Neuroanatomist and experimental Neurpathologist trained in Germany, Switzerland, Hungary, Sweden and USA. His main research interest is currently focused on neurotoxicity of nanoparticle and nanowired drug delivery of agents for enhanced neuroprotection in a variety of CNS insults or neurodegenerative diseases in relation to the blood-brain barrier (BBB) function. He has authored more than 250 original research papers and edited several book volumes or progress in brain research series.

Neurobiology, Nanoneuroscience

Dr. Uzunova is a medical doctor and neuroscientist with experience in the areas of psychiatry, neuropharmacology, rare disorders, neurodevelopmental and neuropsychiatric disorders, molecular and cellular neuroscience, and immunology. She has studied synaptic plasticity, the ratio of excitation and inhibition, oxytocin, dopamine, glutamate and GABA neurotransmitter systems and their role in CNS disorders. Another area of specialization is neurobiology of addiction. She has clinical research experience on development of new therapeutics for major depressive disorder (MDD) and autism spectrum disorders (ASD). She has experience in teaching, mentoring, writing of peer-reviewed publications, grants, book chapters, posters, informed consent forms, presentations, and experience in project management, designing research hypotheses, following through with experimental design, generation, analysis, critical interpretation and presentation of scientific data, and mentoring. She works towards understanding the neurobiological mechanisms and developing of new treatments for neurodevelopmental disorders such as autism spectrum disorders (with focus on syndromal forms of autism), anxiety, mood disorders, and orphan diseases.

Clinical Neuropharmacology, Molecular Neuropharmacology ,Therapeutics for Autism Spectrum Disorders and Rare Diseases,Mood disorders with focus on Depression,

Alain Mititelu is a scientist and dr with more than 25 yrs experience in pharma industry. He is hard working perfectionist and with a great resources of key opinion leaders. He has impressive background in CNS neuroscience psychiatry neurology. He is highly experienced in all aspects of clinical research:phase1-first in man study-proof of concept/phase 2-3/preclinical safety and pharmacovigilance aspects/quality and risk management/valuable in reg affairs submission.

Neurodegenerative Diseases